U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung
Go back to U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung| (NASDAQ: LQDA) | Delayed: 75.49 +4.42 (6.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $71.07 | 52 Week High | $ | |||
| Open | $72.97 | 52 Week Low | $ | |||
| Day High | $76.66 | P/E | N/A | |||
| Day Low | $71.77 | EPS | $ | |||
| Volume | 2,980,363 | |||||
